Nectar Lifescience Ltd

₹ 17.0 -1.28%

25 Jul - close price

About

Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations^[1]

Key Points

Business Overview:^[1]
NLL is a research-driven manufacturer
of Active Pharmaceutical Ingredients, intermediates, and finished dosage
forms, specializing in anti-infectives
like Cephalosporins. It also serves
as a CMO for global pharma
innovators.

Website BSE NSE - BE

Market Cap ₹ 381 Cr.
Current Price ₹ 17.0
High / Low ₹ 56.5 / 15.5
Stock P/E
Book Value ₹ 42.6
Dividend Yield 0.00 %
ROCE -5.36 %
ROE -11.2 %
Face Value ₹ 1.00

Add ratio to table

Edit ratios

Pros

Stock is trading at 0.40 times its book value

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of -6.67% over past five years.
Company has a low return on equity of -5.50% over last 3 years.
Contingent liabilities of Rs.214 Cr.
Promoters have pledged or encumbered 99.6% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
	476	403	389	344	389	394	398	452	441	359	428	455	431
	427	361	396	343	371	359	371	410	393	319	385	410	585
Operating Profit	49	42	-7	1	18	36	27	42	48	40	43	45	-154
OPM %	10%	10%	-2%	0%	5%	9%	7%	9%	11%	11%	10%	10%	-36%
	1	0	11	13	18	0	11	0	1	1	1	1	0
Interest	17	21	21	17	20	18	21	25	24	20	20	17	18
Depreciation	14	15	15	15	15	15	15	15	15	15	16	16	16
Profit before tax	18	6	-32	-18	2	3	2	2	11	5	9	13	-188
Tax %	35%	36%	-31%	-47%	-145%	41%	38%	36%	95%	40%	35%	38%	-31%
	12	4	-22	-9	4	2	1	2	1	3	6	8	-130
EPS in Rs	0.52	0.17	-1.00	-0.41	0.16	0.08	0.05	0.07	0.03	0.13	0.25	0.35	-5.80
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	1,634	1,638	1,674	1,635	1,874	2,779	2,363	1,541	1,665	1,520	1,682	1,673
	1,345	1,371	1,436	1,411	1,638	2,514	2,143	1,432	1,507	1,467	1,530	1,700
Operating Profit	289	267	239	224	236	264	220	109	159	53	152	-26
OPM %	18%	16%	14%	14%	13%	10%	9%	7%	10%	3%	9%	-2%
	12	20	6	23	6	6	4	-22	11	43	15	2
Interest	138	126	123	117	115	148	126	112	79	79	87	75
Depreciation	84	77	57	62	64	63	61	60	57	59	61	62
Profit before tax	78	85	64	67	63	59	37	-85	34	-42	18	-162
Tax %	21%	22%	15%	18%	17%	19%	15%	-14%	26%	-43%	73%	-30%
	62	66	54	55	52	48	32	-73	25	-24	5	-114
EPS in Rs	2.77	2.95	2.42	2.47	2.33	2.12	1.42	-3.27	1.12	-1.08	0.22	-5.07
Dividend Payout %	4%	3%	4%	2%	2%	2%	4%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	0%
5 Years:	-7%
3 Years:	0%
TTM:	-1%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	-2425%

Stock Price CAGR
10 Years:	-7%
5 Years:	-3%
3 Years:	-11%
1 Year:	-47%

Return on Equity
10 Years:	0%
5 Years:	-4%
3 Years:	-6%
Last Year:	-11%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	22	22	22	22	22	22	22	22	22	22	22	22
Reserves	905	936	932	984	1,036	1,083	1,114	1,040	1,065	1,042	1,047	934
	858	925	962	878	955	903	779	903	860	754	636	582
	609	628	640	696	710	696	718	423	443	371	486	509
Total Liabilities	2,394	2,510	2,556	2,581	2,724	2,705	2,633	2,388	2,391	2,189	2,191	2,047
	948	934	906	881	852	825	785	772	723	662	643	633
CWIP	122	91	99	102	100	100	115	99	85	78	66	57
Investments	0	1	1	1	1	1	0	1	1	1	1	1
	1,324	1,485	1,551	1,597	1,771	1,780	1,733	1,517	1,582	1,449	1,482	1,357
Total Assets	2,394	2,510	2,556	2,581	2,724	2,705	2,633	2,388	2,391	2,189	2,191	2,047

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	255	144	169	199	65	239	285	21	95	134	225	169
	-90	-60	-77	-18	-29	-26	-33	-29	17	52	-17	-42
	-161	-61	-89	-204	-40	-201	-252	11	-119	-186	-205	-128
Net Cash Flow	4	23	3	-23	-4	12	-0	4	-8	-0	2	-1

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	84	99	107	112	119	73	61	89	98	67	82	75
Inventory Days	240	253	260	270	226	151	192	185	197	212	215	184
Days Payable	139	146	154	167	142	80	104	108	112	100	127	117
Cash Conversion Cycle	185	207	213	215	203	145	150	166	182	179	170	143
Working Capital Days	152	173	178	186	190	129	149	190	198	204	171	157
ROCE %	12%	11%	10%	10%	9%	10%	8%	3%	5%	-0%	6%	-5%

Shareholding Pattern

Numbers in percentages

19 Recently

	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
	55.80%	55.80%	55.80%	55.80%	55.80%	55.80%	55.80%	55.80%	55.80%	44.53%	44.53%	44.53%
	16.12%	15.99%	16.07%	16.00%	16.02%	16.12%	16.98%	16.60%	3.24%	0.73%	1.65%	0.82%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.15%	0.19%
	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%
	28.06%	28.20%	28.12%	28.18%	28.17%	28.05%	27.20%	27.57%	40.94%	54.72%	53.64%	54.45%
No. of Shareholders	62,940	64,422	62,874	61,582	60,283	60,761	59,946	58,230	66,741	69,482	69,241	71,977

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Jun 2025
	55.80%	55.80%	55.80%	55.80%	55.80%	55.80%	55.80%	55.80%	44.53%	44.53%
	3.39%	3.38%	2.90%	2.90%	2.62%	1.67%	16.07%	16.98%	1.65%	0.82%
	0.83%	0.36%	0.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.15%	0.19%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.02%	0.02%	0.02%	0.02%
	39.98%	40.46%	41.20%	41.30%	41.58%	42.53%	28.12%	27.20%	53.64%	54.45%
No. of Shareholders	36,791	38,709	41,876	40,012	47,394	64,012	62,874	59,946	69,241	71,977

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Nectar Lifescience Ltd

Nectar Lifescience Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls